These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28031519)

  • 1. Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
    Bashir ES; Kwan AK; Chan CY; Mun Keong K
    J Orthop Surg (Hong Kong); 2016 Dec; 24(3):421-423. PubMed ID: 28031519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].
    Durand M; Logerot S; Fonrose X; Schir E
    Therapie; 2014; 69(2):163-8. PubMed ID: 24926635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.
    Hashisako M; Wakamatsu K; Ikegame S; Kumazoe H; Nagata N; Kajiki A
    Tohoku J Exp Med; 2012 Oct; 228(2):163-8. PubMed ID: 23036980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
    Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
    Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
    Liam CK; Pang YK; Leow CH
    Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
    Lange T; Müller-Tidow C; Serve H; Hoffknecht P; Berdel WE; Thomas M
    Oncol Rep; 2005 Dec; 14(6):1539-42. PubMed ID: 16273252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
    Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
    Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
    J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease flare after gefitinib discontinuation.
    Akamatsu H; Ono A; Shukuya T; Tsuya A; Nakamura Y; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N; Takahashi T
    Respir Investig; 2015 Mar; 53(2):68-72. PubMed ID: 25745851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
    Maeda A; Nakata M; Shimizu K; Yukawa T; Saisho S; Okita R
    World J Surg Oncol; 2016 Jun; 14(1):175. PubMed ID: 27495256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
    Zhuang J; Tang X; Du Z; Yang M; Zhou Y
    Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
    Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
    J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of survival in patients with bone metastasis of lung cancer.
    Sugiura H; Yamada K; Sugiura T; Hida T; Mitsudomi T
    Clin Orthop Relat Res; 2008 Mar; 466(3):729-36. PubMed ID: 18196360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.